Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507328 | 0.91 | ALDH1A1 (0.37) | ALDH1A1GLAMTNR1AMTNR1BABCB1 | |
| SCHEMBL21962157 | 0.81 | PTGDR2 (0.35) | ALDH1A1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL25138912 | 0.80 | EGFR (0.33) | ALDH1A1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL23692165 | 0.78 | GPR35 (0.31) | ALDH1A1GPR35 | |
| SCHEMBL23692119 | 0.77 | MTNR1A (0.35) | ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL25139126 | 0.76 | EGFR (0.30) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL20681199 | 0.76 | GABRA1 (0.46) | MTNR1AMTNR1B | |
| SCHEMBL29691372 | 0.74 | DHODH (0.38) | — | |
| SCHEMBL23013322 | 0.74 | DHODH (0.38) | — | |
| SCHEMBL22014709 | 0.74 | ABCC9 (0.32) | ALDH1A1ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 2123/4885GLA 1833/4885MTNR1A 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.